Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection

被引:5
作者
Munari, Enrico [1 ]
Querzoli, Giulia [2 ]
Brunelli, Matteo [3 ]
Marconi, Marcella [4 ]
Sommaggio, Marco [5 ]
Cocchi, Marco A. [1 ]
Martignoni, Guido [3 ,6 ]
Netto, George J. [7 ]
Calio, Anna [3 ]
Quatrini, Linda [8 ]
Mariotti, Francesca R. [8 ]
Luchini, Claudio [3 ]
Girolami, Ilaria [9 ]
Eccher, Albino [2 ]
Segala, Diego [10 ]
Ciompi, Francesco [11 ]
Zamboni, Giuseppe [3 ,4 ]
Moretta, Lorenzo [8 ]
Bogina, Giuseppe [4 ]
机构
[1] Univ Brescia, Dept Mol & Translat Med, Pathol Unit, Brescia, Italy
[2] Univ & Hosp Trust Verona, Dept Pathol & Diagnost, Verona, Italy
[3] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Pathol Unit, Verona, Italy
[4] IRCCS Sacro Cuore Don Calabria Hosp, Pathol Unit, Verona, Italy
[5] Carlo Poma Hosp, Lab Med, Mantua, Italy
[6] Pederzoli Hosp, Pathol Unit, Verona, Italy
[7] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA
[8] Bambino Gesu Childrens Hosp IRCCS, Tumor Immunol Unit, Rome, Italy
[9] Cent Hosp Bolzano, Pathol Unit, Bolzano, Italy
[10] ASST Spedali Civili, Pathol Unit, Brescia, Italy
[11] Radboud Univ Nijmegen, Dept Pathol, Computat Pathol Grp, Med Ctr, Nijmegen, Netherlands
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-L1; immunohistochemistry; assays; comparison; urothelial; bladder; cancer; prediction; PEMBROLIZUMAB; ATEZOLIZUMAB; THERAPY;
D O I
10.3389/fimmu.2022.954910
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Different programmed cell death-ligand 1 (PD-L1) assays and scoring algorithms are being used in the evaluation of PD-L1 expression for the selection of patients for immunotherapy in specific settings of advanced urothelial carcinoma (UC). In this paper, we sought to investigate three approved assays (Ventana SP142 and SP263, and Dako 22C3) in UC with emphasis on implications for patient selection for atezolizumab/pembrolizumab as the first line of treatment. Tumors from 124 patients with invasive UC of the bladder were analyzed using tissue microarrays (TMA). Serial sections were stained with SP263 and SP142 on Ventana Benchmark Ultra and with 22C3 on Dako Autostainer Link 48. Stains were evaluated independently by two observers and scored using the combined positive score (CPS) and tumor infiltrating immune cells (IC) algorithms. Differences in proportions (DP), overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen kappa were calculated for all comparable cases. Good overall concordance in analytic performance was observed for 22C3 and SP263 with both scoring algorithms; specifically, the highest OPA was observed between 22C3 and SP263 (89.6%) when using CPS. On the other hand, SP142 consistently showed lower positivity rates with high differences in proportions (DP) compared with 22C3 and SP263 with both CPS and IC, and with a low PPA, especially when using the CPS algorithm. In conclusion, 22C3 and SP263 assays show comparable analytical performance while SP142 shows divergent staining results, with important implications for the selection of patients for both pembrolizumab and atezolizumab.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
    Wang, Xinran
    He, Jiankun
    Li, Jinze
    Wu, Chun
    Yue, Meng
    Niu, Shuyao
    Jia, Ying
    Jia, Zhanli
    Cai, Lijing
    Liu, Yueping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
  • [42] Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC)
    Xinran Wang
    Jiankun He
    Jinze Li
    Chun Wu
    Meng Yue
    Shuyao Niu
    Ying Jia
    Zhanli Jia
    Lijing Cai
    Yueping Liu
    Journal of Cancer Research and Clinical Oncology, 150
  • [43] Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens
    Kim, So-Woon
    Jeong, Gowun
    Ryu, Min-Hee
    Park, Young Soo
    PATHOLOGY, 2021, 53 (05) : 586 - 594
  • [44] PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma
    Brown, Landon C.
    Zhu, Jason
    Labriola, Matthew K.
    Wu, Yuan
    Cheris, Sachica
    Liu, Xin
    Perkinson, Kathryn
    Su, Zuowei
    McCall, Shannon
    Huang, Jiaoti
    Foo, Wen-Chi
    Gupta, Rajan T.
    Armstrong, Andrew J.
    George, Daniel J.
    Harrison, Michael R.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 509 - 513
  • [45] Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies
    Hofman, Veronique
    Ilie, Marius
    Long, Elodie
    Butori, Catherine
    Lassalle, Sandra
    Washetine, Kevin
    Lalve, Salome
    Marquette, Charles-Hugo
    Soria, Jean-Charles
    Hofman, Paul
    BULLETIN DU CANCER, 2016, 103 (04) : 368 - 380
  • [46] Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
    Zhu, Jason
    Armstrong, Andrew J.
    Friedlander, Terence W.
    Kim, Won
    Pal, Sumanta K.
    George, Daniel J.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [47] PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma
    Arriola, Aileen Grace P.
    Farahani, Sahar J.
    Bhargava, Hersh K.
    Guzzo, Thomas J.
    Brooks, John S. J.
    Lal, Priti
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 151 (06) : 561 - 573
  • [48] The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
    Wen, Yaoan
    Chen, Yeda
    Duan, Xiaolu
    Zhu, Wei
    Cai, Chao
    Deng, Tuo
    Zeng, Guohua
    CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (04) : 407 - 416
  • [49] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [50] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385